CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 0.7%

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares dropped 0.7% on Friday . The company traded as low as $1.45 and last traded at $1.48. Approximately 2,369 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 39,923 shares. The stock had previously closed at $1.49.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.

CytoMed Therapeutics Trading Down 0.7 %

The firm has a 50 day moving average of $1.81 and a two-hundred day moving average of $2.01. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.09 and a quick ratio of 14.09.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.